Non-adherence to eye care in people with diabetes by Murchison, Ann P. et al.
Thomas Jefferson University
Jefferson Digital Commons
Wills Eye Hospital Papers Wills Eye Hospital
7-1-2017
Non-adherence to eye care in people with diabetes
Ann P. Murchison
Thomas Jefferson University, AMurchison@WillsEye.org
Lisa A. Hark
Thomas Jefferson University
Laura T. Pizzi
Thomas Jefferson University, laura.pizzi@jefferson.edu
Yang Dai
Wills Eye Hospital
Eileen Mayro
Wills Eye Hospital, Eileen.Mayro@jefferson.edu
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: https://jdc.jefferson.edu/willsfp
Part of the Ophthalmology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Wills Eye Hospital Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Murchison, Ann P.; Hark, Lisa A.; Pizzi, Laura T.; Dai, Yang; Mayro, Eileen; Storey, Philip P.; Leiby,
Benjamin E.; and Haller, Julia A., "Non-adherence to eye care in people with diabetes" (2017). Wills
Eye Hospital Papers. Paper 71.
https://jdc.jefferson.edu/willsfp/71
Authors
Ann P. Murchison, Lisa A. Hark, Laura T. Pizzi, Yang Dai, Eileen Mayro, Philip P. Storey, Benjamin E. Leiby,
and Julia A. Haller
This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/willsfp/71
BMJ Open Diab Res Care 2017;5:e000333. doi:10.1136/bmjdrc-2016-000333 1
Open Access 
AbstrAct
Objective Evaluate individual factors that impact 
adherence to eye care follow-up in patients with diabetes.
Design and methods A 4-year retrospective chart review 
was conducted for 1968 patients with diabetes over age 
40 from an urban academic center. Data collected included 
demographics, insurance, visual acuity, smoking status, 
medications, dates of dilated fundus examinations (DFE), 
and reported hemoglobin A1C and blood glucose levels. 
The primary outcome was timely DFE follow-up adherence 
following the initial eye exam visit.
Results Overall, 41.6% of patients adhered to initial 
follow-up eye care recommendations. Multivariable 
analysis demonstrated that patients with severe diabetic 
retinopathy (DR) were more adherent than patients 
with mild DR (OR 1.86). Other variables associated with 
increased adherence were visual impairment and reported 
A1C or blood glucose. Smoking was associated with 
decreased adherence. Ethnicity and insurance were also 
significantly associated with adherence. Longitudinal 
follow-up rates were influenced by additional factors, 
including ethnicity and neighborhood deprivation index.
Conclusions Patients with moderate to severe DR and/
or visual impairment were more likely to adhere to timely 
DFE follow-up. This could relate to the presence of 
visual symptoms and/or other systemic manifestations 
of diabetes. Smokers were less likely to adhere to timely 
DFE follow-up. One hypothesis is patients who smoke 
have other symptomatic health problems which patients 
prioritize over asymptomatic ocular disorders. In order to 
reduce vision loss from DR, practitioners should be aware 
that patients with mild and moderate DR, patients with 
normal vision, and smokers are at greater risk for poor 
follow-up eye care adherence.
IntroductIon
Approximately, 285 million people worldwide 
have been diagnosed with diabetes.1 It is esti-
mated that by 2025, 53.1 million Americans 
will be affected by diabetes, representing a 
projected increase of 64% from 2010.2 Diabetic 
retinopathy (DR) is the most common 
complication of diabetes and a leading cause 
of blindness in the USA and other countries.3 
Almost all people with diabetes will develop 
some degree of DR, with incidence increasing 
with longer duration of diabetes.4 A retinal 
vascular disorder, DR results in microvascular 
damage and leads to retinal ischemia and 
increased vascular permeability. Estimates of 
DR and vision-threatening DR prevalence in 
US adults with diabetes are 28.5% and 4.4%, 
respectively.5 In 2004, blindness from DR 
accounted for approximately US$ 500 million 
in direct medical costs among Americans 
age 40 and older.6 Improving the detection, 
management, and treatment of DR could save 
between US$62.1 and 108.6 million in annual 
costs to the federal government.4 Due to the 
advancing age of the population and growing 
rates of obesity across all ethnic groups, the 
medical and financial costs of diabetes and 
DR in the USA continue to rise.6
Management of DR includes early identifi-
cation, regular eye examinations, aggressive 
control of hyperglycemia and hypertension, 
as well as medical and/or surgical ocular 
treatment(s). The American Diabetes Asso-
ciation and the American Academy of 
Ophthalmology recommend dilated fundus 
examinations (DFEs) for all people with 
diabetes at least once a year and more frequent 
exams for more advanced DR.7 8 However, 
only between 50% and 60% of Americans with 
significance of this study
What is already known about this subject?
 ► Factors known to impact overall eye care utilization 
include age, ethnicity, socioeconomic status, sex, 
and insurance status.
 ► Less than 60% of Americans with diabetes adhere to 
recommendations for annual eye exams.
What are the new findings?
 ► Multiple factors impacted adherence to eye exams 
in this population with diabetes, including severity 
of diabetic retinopathy, ethnicity, and reporting of 
hemoglobin A1C or blood sugar.
 ► Smoking status is a new risk factor impacting 
adherence in our population.
How might these results change the focus of 
research or clinical practice?
 ► Understanding the risk stratification for adherence 
in patients with diabetes may impact clinical 
recommendations.
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Table 1 ICD-9 codes and American Academy of Ophthalmology recommended follow-up times for patients with diabetes 
stratified by severity of diabetic retinopathy8
Category ICD-9 code and diagnosis Recommended DFE follow-up Acceptable DFE follow-up
Mild 250.00 (DM) 12 months 15 months
362.01 Background NPDR
352.03 NOS NPDR
Moderate 362.04 Mild NPDR 6–12 months 12 months
362.05 Moderate NPDR
Severe 362.06 Severe NPDR 2–4 months 4 months
362.02 PDR
DFE, dilated fundus examination; DM, diabetes mellitus; ICD-9, International Classification of Diseases, Ninth Revision; NOS, not otherwise 
specified; NPDR; non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.
Clinical Care/Education/Nutrition/Psychosocial Research
diabetes receive annual DFEs,9 with rates even lower in 
underserved and racial/ethnic minority populations.10–12 
In order to reduce the prevalence of eye disease and 
improve patients’ quality of life, Healthy People 2020 aims 
to increase the proportion of adults with diabetes who 
have comprehensive eye examinations.9 One method to 
achieve this goal is to implement targeted interventions 
for patients at risk for low adherence. Studies have shown 
that age,6 12–15 gender,12 14 16 ethnicity,13–15 17–19 socioeco-
nomic status,6 12 14 17 19 20 and insurance coverage6 16–18 21–23 
affect utilization of eye care services. However, limited 
research has documented the factors associated with 
adherence to established recommendations for DFE 
follow-up. Most research to date assessing DFE adher-
ence has used survey methods.24 Self-reported data are 
limited not only due to response bias but also in the 
clinical variables that can be collected. In addition, most 
research has only assessed whether patients with diabetes 
receive an annual eye examination and does not take 
into account the severity of DR.
Therefore, this study aims to (1) identify factors 
associated with short-term adherence to DFE within a 
recommended time frame following an index visit for 
a large cohort of patients with diabetes in an urban eye 
care setting, (2) identify the factors that impact longi-
tudinal utilization of DFE services and (3) compare the 
individual, clinical, and system-level factors that impact 
DFE follow-up adherence by severity of DR. With this 
data, we aim to identify the characteristics of patients at 
high risk for poor adherence to DFE follow-up.
reseArch desIgn And methods
Following institutional review board approval, a data-
base was developed using billing and administrative 
information of patients over age 40 who had their initial 
visit to a general ophthalmology or retina clinic within 
an urban academic eye hospital between 1 January 2007 
and 12 December 2010. Patients with diabetes were 
identified in the claims files using International Classi-
fication of Diseases, Ninth Revision (ICD-9) diagnosis 
codes for diabetes ( 250. xx) and/or DR ( 362. xx). At each 
encounter, patients were classified by their level of DR 
severity (mild, moderate, and severe) in the more severe 
eye using ICD codes documented in claims (table 1). 
Patients with diabetes without DR were included in the 
mild category based on same follow-up recommenda-
tions.
Patient charts were reviewed to determine additional 
clinical information and confirm eligibility. All chart 
reviewers were research assistants and coordinators 
trained in the review process using sample charts that 
had been reviewed by an ophthalmologist. After training, 
each reviewer’s work was evaluated in detail and additional 
focused training was conducted to assure a standardized 
chart review process. Patient insurance status from their 
index visit was recorded from billing data. From the 
chart review, patients’ first reported hemoglobin A1C 
(HbA1C) and blood sugar levels, age, gender, ethnicity, 
current smoking status, prescription for glasses, visual 
acuity, diagnosis of other eye diseases, dates of DFEs, and 
medications were recorded. Medications noted included 
insulin, non-insulin diabetes medication, medications to 
treat hypertension, medications to treat hyperlipidemia, 
and medications to treat the mental health conditions 
of anxiety and/or depression. An investigator with a 
doctorate in pharmacy compiled the list of all medi-
cations for each category. Best-corrected visual acuity 
(BCVA) in the worse eye was categorized as normal vision 
(20/60 or better) or visual impairment (20/70 or worse). 
Driving distance is calculated based on the calculations 
using the eye clinic and patient addresses. Socioeconomic 
status was estimated using a patient’s home census tract 
based on a previously described standardized neighbor-
hood deprivation index.25 If ethnicity was not recorded 
in the chart, reviewers obtained it from the patient’s driv-
er’s license when available. When ethnicity could not be 
determined from the chart or the driver’s license, it was 
imputed using a previously validated approach based on 
patients’ last names and 2010 Census tract location.26 27
The index visit was defined as the date of the first 
DFE in this eye care system including a diagnosis of 
type 1 or type 2 diabetes or DR. Patients who did not 
have a documented DFE at the designated eye clinics 
within 30 days of type 1/type 2 diabetes or DR noted 
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in their billing records were removed from the sample, 
as we were unable to define the index visit and hence 
the recommended follow-up time for these individuals. 
The diagnosis of diabetes did not have to be new to 
the patients. For the short-term adherence measure, 
subjects were defined as adherent if they obtained a 
DFE within the recommended time after their index 
visit. Acceptable follow-up was defined as within 15 
months for mild DR, within 12 months for moderate 
DR and within 4 months from the index visit for severe 
DR (table 1).
This study also assessed longitudinal utilization of DFE 
services. Longitudinal utilization was measured by the 
number of DFEs per year over the 4-year study. After the 
index visit, the severity of DR and the date of each DFE 
follow-up visit were recorded over the 4-year period.
data analysis
Descriptive statistics (frequencies, ranges, mean, SD) 
were calculated to summarize the sample characteristics. 
Associations between individual, clinical, system infor-
mation, and DFE follow-up adherence were evaluated 
using χ2 tests. Logistic regression was used to evaluate the 
adjusted impact of individual, clinical, and system-level 
factors related to DFE follow-up adherence. All variables 
associated with adherence in the univariable analyses 
(p<0.20) were included in the multivariable logistic 
regression model, and a backward elimination procedure 
was used to sequentially remove non-significant terms 
until all variables had p<0.20. The number of DFEs over 
the entire follow-up period was modeled using Poisson 
regression with follow-up time as the offset term. The 
same variable selection procedure was used to develop 
a multivariable model as used for initial DFE adherence. 
Final multivariable logistic and Poisson models were 
developed for the entire cohort, for subjects classified 
with mild DR at the index visit, and for subjects classi-
fied with severe DR at the index visit. The distribution 
of time from index visit to first follow-up DFE was esti-
mated using the Kaplan-Meier method. All analyses were 
performed using SAS V.9.2 or later (SAS Institute, Cary, 
North Carolina, USA).
results
Billing data indicated that 2238 patients with diabetes 
had an initial visit at the general ophthalmology or retina 
clinic between 1 January 2007 and 31 December 2010. 
Charts of 2179 patients were available for review. Addi-
tional patients were excluded who had a visit prior to 
2007 (n=23), no DFE within 30 days of the index visit 
(n=128), or insufficient time between the index visit 
and review date to allow for recommended follow-up 
(n=60), leaving a total of 1968 patients included in this 
study. The mean age of included patients was 59.4 years 
(SD 10.9 years) with a range of 40–93 years. The median 
of follow-up time was 2.74 years (range of 0.70–5.72 
years).
Adherence to initial dFe follow-up
Overall, 41.6% of individuals were adherent to the initial 
recommended follow-up DFE after the index visit with an 
average of 0.61 DFEs per year over the entire follow-up 
period. Adherence to initial DFE follow-up and longitu-
dinal utilization of DFE services were evaluated by patient 
characteristics (table 2). For initial DFE follow-up, 
severity of DR was significantly associated with adherence 
(p<0.0001), with patients with mild DR being the least 
likely to follow-up in a timely manner. Over the 4-year 
period, 35.1% of patients with mild or no DR completed 
DFEs within the recommended follow-up time period (15 
months) compared with 44.0% of patients with moderate 
DR (12 months) and 65.4% of patients with severe DR (4 
months). The median time to initial follow-up was 21 days 
for severe patients, 127 days for moderate patients, and 
246 days for mild patients. Patients under 65 years were 
less likely to adhere to follow-up recommendations than 
those over 65 (p=0.0043). Patients with visual impairment 
in the worse eye were more adherent to follow-up than 
patients with normal vision (p<0.0001). Ethnicity also 
impacted adherence (p=0.0047) with adherence ranging 
from 40.73% to 47.37% by group. Smokers were less 
likely to follow-up than non-smokers (p<0.0001). Other 
factors that were significantly associated with adherence 
to first DFE follow-up in the univariable analyses included 
the presence of HbA1C documentation (p<0.0001), 
blood sugar documentation (p<0.0001), insulin use 
(p<0.0001), diagnosis of cataract (p<0.0001), glaucoma 
(p=0.0053), non-diabetic retinal disease (p<0.0001), and 
other ocular comorbidities (p<0.0001). Insurance status 
(p=0.0008) was significantly associated with adherence 
with patients with Medicaid coverage having the lowest 
adherence for the first DFE follow-up. Absence of mental 
health medication use was also associated with higher 
adherence (p=0.013).
longitudinal utilization of dFe services
As for adherence to DFE follow-up, severity of DR 
(p<0.0001), visual impairment in the worse eye 
(p<0.0001), HbA1C documentation (p<0.0001), 
blood sugar documentation (p<0.0001), smoking 
status (p<0.0001), insurance (p=0.0095), insulin use 
(p<0.0001), mental health medicine use (p<0.0001), 
non-diabetic retinal disease diagnosis (p<0.0001), and 
other ocular comorbidity diagnosis (p<0.0001) were 
significantly associated with number of DFEs per year 
in the univariable analysis (table 2). Insurance through 
Medicaid, current smoking and mental health medi-
cine use were associated with lower utilization. The 
presence of all other factors was associated with higher 
use. In addition, ethnicity (p=0.0047), prescription for 
glasses (p=0.0001), neighborhood deprivation index 
(p=0.0057), hyperlipidemia medication use (p=0.047), 
and driving distance (p=0.0066) were associated with 
number of DFEs per year but not with initial DFE 
follow-up. Patients of Asian race/ethnicity had the 
higher utilization than other groups as did those in the 
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Table 2 DFE follow-up and longitudinal utilization univariable analysis by patient characteristics
Variable Values n
Adherence to initial 
follow-up
Number of DFEs per year over 
entire follow-up period
 n (%) p Value
Mean
(95% CI) p Value
Severity Severe 393 257 (65.39) <0.0001 1.45 (1.34 to 1.58) <0.0001
Moderate 107 47 (43.93) 0.54 (0.42 to 0.71)
  Mild 1468 515 (35.08) 0.39 (0.36 to 0.43)
Gender F 1077 432 (40.11) 0.13 0.58 (0.54 to 0.64) 0.16
M 890 387 (43.48) 0.64 (0.58 to 0.70)
Age <65 1369 541 (39.52) 0.0043 0.61 (0.57 to 0.66) 0.70
≥ 65 599 278 (46.41) 0.60 (0.53 to 0.67)
Ethnicity/race African-American 1321 538 (40.73) 0.58 0.57 (0.53 to 0.62) 0.0047
Asian 76 36 (47.37) 0.93 (0.72 to 1.19)
Caucasian 391 164 (41.94) 0.59 (0.51 to 0.68)
Latino/Hispanic 139 62 (44.6) 0.69 (0.55 to 0.86)
BCVA in worse eye Normal vision (20/60 or 
better)
1369 455 (33.24) <0.0001 0.44 (0.40 to 0.48) <0.0001
Visual impairment (20/70 or 
worse)
537 339 (63.13) 1.05 (0.96 to 1.15)
HbA1c in chart Yes 482 244 (50.62) <0.0001 0.90 (0.82 to 1.00) <0.0001
No 1486 575 (38.69) 0.51 (0.48 to 0.56)
Blood sugar in chart Yes 1350 612 (45.33) <0.0001 0.70 (0.65 to 0.75) <0.0001
No 618 207 (33.5) 0.42 (0.36 to 0.48)
Wears glasses Yes 1257 500 (39.78) 0.11 0.54 (0.5 to 0.59) 0.0001
No 675 294 (43.56) 0.7 (0.64 to 0.78)
Current smoking 
status
Yes 406 117 (28.82) <0.0001 0.4 (0.33 to 0.47) <0.0001
No 1537 697 (45.35) 0.67 (0.63 to 0.72)
Insurance No insurance 340 147 (43.24) 0.0008 0.69 (0.6 to 0.8) 0.0095
Medicaid 555 199 (35.86) 0.52 (0.45 to 0.59)
Medicare 413 204 (49.39) 0.66 (0.58 to 0.75)
Medicaid+Medicare 40 14 (35) 0.4 (0.23 to 0.71)
Private/other/vision 620 255 (41.13) 0.62 (0.55 to 0.69)
Neighborhood 
deprivation index
1 (low SES) 1375 561 (40.8) 0.27 0.58 (0.54 to 0.63) 0.0057
2 345 146 (42.32) 0.75 (0.65 to 0.85)
3 138 68 (49.28) 0.49 (0.38 to 0.64)
4 (high SES) 110 44 (40) 0.62 (0.47 to 0.81)
Medications (insulin) Yes 571 280 (49.04) <0.0001 0.75 (0.68 to 0.83) <0.0001
No 1397 539 (38.58) 0.55 (0.51 to 0.59)
Medications 
(diabetes)
Yes 1507 624 (41.41) 0.73 0.59 (0.55 to 0.64) 0.13
No 461 195 (42.3) 0.66 (0.58 to 0.75)
Medications 
(hypertension)
Yes 1230 522 (42.44) 0.34 0.60 (0.55 to 0.65) 0.54
No 738 297 (40.24) 0.62 (0.56 to 0.69)
Medications 
(hyperlipidemia)
Yes 742 322 (43.4) 0.21 0.56 (0.5 to 0.62) 0.047
No 1226 497 (40.54) 0.64 (0.59 to 0.69)
Medications (mental 
health)
Yes 242 83 (34.30) 0.013 0.41 (0.33 to 0.51) <0.0001
No 1666 712 (42.74) 0.64 (0.60 to 0.68)
Continued
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Variable Values n
Adherence to initial 
follow-up
Number of DFEs per year over 
entire follow-up period
 n (%) p Value
Mean
(95% CI) p Value
Driving distance 0–5 miles 665 278 (41.8) 0.40 0.52 (0.47 to 0.59) 0.0066
5–25 miles 1116 455 (40.77) 0.66 (0.6 to 0.71)
≥25 miles 187 86 (45.99) 0.62 (0.51 to 0.76)
Cataract Yes 321 168 (52.34) <0.0001 0.67 (0.57 to 0.78) 0.21
No 1647 651 (39.53) 0.60 (0.56 to 0.64)
Glaucoma Yes 192 98 (51.04) 0.0053 0.68 (0.56 to 0.82) 0.26
No 1776 721 (40.6) 0.60 (0.56 to 0.64)
Non-diabetic retinal 
disease
Yes 203 156 (76.85) <0.0001 1.46 (1.3 to 1.64) <0.0001
No 1765 663 (37.56) 0.5 (0.47 to 0.54)
Other ocular 
comorbidity
Yes 1222 568 (46.48) <0.0001 0.71 (0.65 to 0.76) <0.0001
No 746 251 (33.65) 0.46 (0.41 to 0.51)
Bold indicates p values that reach significance.
DFE, dilated fundus exam; BCVA, best-corrected visual acuity; HbA1c,hemoglobin A1c; SES, socioeconomic status.
Table 2 Continued 
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second quartile of SES, those closest to Wills, and those 
not using hyperlipidemia medications.
multivariable analysis of factors affecting initial dFe follow-
up overall and by severity of dr
In the final multivariable logistic regression model of the 
full cohort, severity of DR, visual impairment in the worse 
eye, HbA1C documentation, blood sugar documentation, 
smoking status, diagnosis of cataract, glaucoma, non-dia-
betic retinal disease, and other ocular comorbidities were 
significantly associated with initial DFE follow-up adher-
ence (table 3). Patients with severe DR had 1.86 times 
(95% CI 1.39 to 2.50) higher odds of adherence to initial 
follow-up recommendations than patients with mild DR.
Patients with severe DR, over age 65 were less likely 
than younger patients to follow-up (OR 0.57; 95% CI 0.33 
to 1.00). In patients with mild DR, visual impairment 
in the worse eye (p<0.0001), HbA1C documentation 
(p<0.0001), blood sugar documentation (p<0.0001), 
negative smoking status (p<0.0001), diagnosis of cata-
ract (p=0.012), glaucoma (p=0.032), non-diabetic 
retinal disease (p<0.0001), or other ocular comorbidi-
ties (p=0.0032) were associated with a higher likelihood 
of adhering to initial DFE follow-up recommendations. 
In patients with severe DR, only age (p=0.049), visual 
impairment in the worse eye (p=0.0018), blood sugar 
documentation (p=0.0038), and non-diabetic retinal 
disease diagnosis (p=0.030) were associated with increased 
likelihood of adherence to initial DFE follow-up.
multivariable analysis of factors affecting longitudinal 
utilization overall and by severity of dr
In the full sample, the multivariable Poisson regression 
model for longitudinal utilization revealed that severity 
of DR (p<0.0001), ethnicity (p=0.028), visual impairment 
in the worse eye (p<0.0001), HbA1C documentation 
(p<0.0001), blood sugar documentation (p<0.0001), 
smoking status (p<0.0001), non-diabetic retinal disease 
(p<0.0001), other ocular comorbidities (p<0.0001), 
and neighborhood deprivation index (NDI) (p=0.032) 
were associated with longitudinal utilization of DFE 
services (table 4). Patients with severe DR had 2.77 times 
(95% CI 2.36 to 3.24) as many DFE appointments per 
year compared with patients with mild or no DR. Patients 
with visual impairment in the worse eye had 1.37 times 
(95% CI 1.19 to 1.57) as many DFE appointments per 
year as patients with normal vision. Patients with HbA1C 
and blood sugar documentation had 1.65 times (95% CI 
1.47 to 1.86 and 1.43 to 1.89) as many DFE appointments 
as patients without documentation, respectively. Patients 
who smoke had 0.72 times (95% CI 0.61 to 0.85) as many 
DFEs per year as non-smokers.
When stratifying by severity, ethnicity (p=0.0052), visual 
impairment in the worse eye (p<0.001), NDI (p=0.015), 
and diagnosis of other ocular comorbidity (p=0.0006) 
were associated with longitudinal utilization in patients 
with mild DR but not in patients with severe disease. All 
factors associated with longitudinal utilization in patients 
with severe DR were also associated with longitudinal 
utilization in patients with mild DR.
conclusIons
In our sample, rates of adherence to follow-up DFE 
recommendations were disappointingly low across all 
ages and ethnic groups, ranging from 35% to 65% adher-
ence depending on the severity of DR. Longitudinal 
utilization was also below recommendations, with the 
annual DFE rate being substantially less than 1 DFE per 
year for patients with mild and moderate DR and less 
than 2 DFEs per year for patients with severe DR.
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Table 4 Final multivariable Poisson regression models for total number of DFEs over the follow-up period
Variable
All patients Mild Severe
 Adjusted IRR p Value Adjusted IRR p Value Adjusted IRR p Value
Severity
(vs mild*)
Moderate 1.30 (0.96, 1.76) <0.0001
Severe 2.77 (2.36, 3.24)
Gender
(male vs female*)
1.10 (0.99, 1.23) 0.085 † †
Ethnicity/race
(vs African-
American*)
Asian 1.22 (0.91, 1.63) 0.028 0.86 (0.54, 1.38) 0.0052 1.55 (0.97, 2.47) 0.14
Caucasian 0.84 (0.69, 1.03) 0.76 (0.58, 0.99) 0.98 (0.68, 1.43)
Latino/Hispanic 1.07 (0.83, 1.37) 1.30 (0.97, 1.74) 0.95 (0.58, 1.55)
Age
(≥65 vs <65*)
† 1.11 (0.96, 1.29) 0.15 0.81 (0.63, 1.05) 0.10
BCVA in worse eye
(visual impairment vs normal*)
1.37 (1.19, 1.57) <0.0001 1.54 (1.31, 1.81) <0.0001 †
HbA1C documented
(yes vs no*)
1.65 (1.47, 1.86) <0.0001 1.71 (1.48, 1.97) <0.0001 1.54 (1.21, 1.97) 0.0006
Blood sugar documented
(yes vs no*)
1.65 (1.43, 1.89) <0.0001 1.62 (1.36, 1.93) <0.0001 1.55 (1.20, 2.00) 0.0006
Wears glasses
(yes vs no*)
1.12 (0.99, 1.26) 0.072 † †
Current smoking status
(smoker vs no*)
0.72 (0.61, 0.85) <0.0001 0.76 0.63, 0.91) 0.0020 0.70 (0.49, 1.01) 0.049
Medication (Insulin)
(yes vs no*)
1.10 (0.97, 1.26) 0.15 1.14 (0.99, 1.33) 0.076 †
Non-insulin diabetic 
medication
(yes vs no*)
0.87 (0.75, 1.01) 0.069 † †
Medications (mental health)
(yes vs no*)
0.82 (0.67, 1.01) 0.051 † 0.60 (0.34, 1.08) 0.070
Cataract
(yes vs no*)
1.12 (0.97, 1.30) 0.13 1.16 (0.98, 1.38) 0.090 †
Glaucoma
(yes vs no*)
† 1.23 (0.99, 1.53) 0.067 †
Non-diabetic retinal disease
(yes vs no*)
1.71 (1.49, 1.96) <0.0001 2.27 (1.89, 2.73) <0.0001 1.38 (1.09, 1.74) 0.0089
Other ocular comorbidity
(yes vs no*)
1.27 (1.13, 1.44) <0.0001 1.28 (1.11, 1.47) 0.0006 †
Neighborhood 
deprivation 
index
(vs lowest 
quartile)
Moderately low 1.17 (0.97, 1.41) 0.032 1.08 (0.86, 1.36) 0.015 1.17 (0.81, 1.70) 0.20
Moderately 
high
0.81 (0.59, 1.12) 0.96 (0.68, 1.38) 0.70 (0.36, 1.35)
High 0.95 (0.68, 1.33) 0.54 (0.31, 0.93) 1.17 (0.67, 2.05)
Driving 
distance
(vs 0–5 miles)
5–25 miles 1.01 (0.87, 1.17) 0.15 † 1.10 (0.80, 1.51) 0.10
≥25 miles 0.83 (0.64, 1.07) 0.76 (0.47, 1.22)
*Reference group.
†Removed from final model via backwards elimination (p>0.2).
Bold indicates p values that reach significance.
BCVA, best-corrected visual acuity; DFE, dilated fundus exam; HbA1c, hemoglobin A1c; IRR, incidence rate ratio.
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For over two decades, it has been well known that 
early identification and treatment can prevent at least 
50% of severe vision loss in patients with DR.28 Previous 
studies have evaluated eye care utilization associations 
on a population level based on self-reported data, but 
this is the first study to analyze clinical and demographic 
characteristics of patients who do and do not adhere 
to follow-up DFE guidelines in a large, urban academic 
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setting. This is also the first study to examine DFE adher-
ence by severity of DR and the individual, clinical, and 
system-level factors that impact longitudinal utilization of 
DFE services.
statistically significant variables after adjustment
Our results indicate that severity of DR is independently 
and strongly associated with adherence to timely DFEs. 
Specifically, patients with mild or no DR were the least 
likely to adhere to follow-up recommendations. We 
hypothesize several reasons for this association. First, 
patients with mild DR might not seek regular ophthalmic 
care because of a lack of perceived need—particularly 
because visual symptoms may be minimal or absent and 
lower severity of DR is associated with fewer systemic 
manifestations.29 In addition, up to half of individuals 
with moderate-to-severe visual loss do not seek regular 
eye care because they do not perceive a need for care.18 30 
It is also possible that patients in our study with mild 
or no DR had less contact with medical professionals 
perhaps due to being generally younger and having less 
time available due to competing commitments (eg, work 
or family). Thus, they may have less encouragement to 
regularly follow-up with their eye care provider. Lastly, 
there could be other factors not yet explored. There-
fore, this association identifies a population that can be 
targeted with educational interventions to increase rates 
of eye care utilization among people with diabetes.
Population-based studies have consistently found 
diabetic eye care utilization to be associated with visual 
impairment.12–14 In our population, after adjusting for 
known risk factors, patients with visual impairment were 
more likely than patients with normal vision to adhere 
to initial follow-up DFE recommendations and use DFE 
services longitudinally. Presumably, visual loss motivates 
patients to obtain eye care.
Our study is also the first to find a relationship between 
smoking status and adherence with diabetic eye care: 
smokers were less likely than non-smokers to adhere 
to the recommended DFE follow-up and smokers had 
lower longitudinal utilization of DFE services, even 
when controlling for other variables. Smoking is related 
to multiple microvascular complications of diabetes, 
although smoking’s specific effect on retinopathy has 
not been well defined.31 Smoking has also been directly 
linked to two of the leading causes of vision loss, cata-
racts, and macular degeneration,32 and may contribute 
to glaucoma.33 Smokers have been shown to use more 
healthcare services at a higher cost than non-smokers, 
which is in contrast to our findings of lower eye care utili-
zation among individuals with diabetes who smoke.34 It is 
unclear why smoking is independently associated with less 
follow-up adherence. Perhaps, patients who smoke have 
other symptomatic health problems which patients give 
priority over asymptomatic or less symptomatic ocular 
disorders. People with diabetes who smoke may place less 
value on eye care given that smokers have worse overall 
health compared with non-smokers, leading to other 
illnesses superseding the perceived need for eye exam-
inations.35 Smokers also tend to be less educated than 
non-smokers and may not understand the importance of 
known health recommendations, which may contribute 
to the differences between the groups.36 Additionally, 
self-management of diabetes is difficult, as attested to 
in multiple studies and addictions such as nicotine may 
impact self-management strategies.
Whether or not self-reported HbA1C or blood glucose 
was mentioned in a patient’s chart was found to be 
significantly associated with DFE adherence rates and 
with increased longitudinal utilization, which was unex-
pected.37 Since HbA1C and blood glucose were from 
patient’s self-report, it is possible that these patients are, in 
general, more informed and involved in their healthcare 
and therefore more likely to adhere to recommenda-
tions. However, since three-quarters of our patients were 
missing HbA1C values and one-third of patients were 
missing blood glucose, we did not evaluate relationships 
between level of HbA1C or blood glucose and adherence 
or other variables. While an objective marker of diabetes 
control would have been useful, the data could not be 
correlated with actual HbA1C or blood glucose, as it was 
subject to recall bias.
Caucasian ethnicity has been associated with higher 
rates of DFEs compared with African-Americans and 
Latinos with diabetes,10 13 14 16 18 which is particularly 
concerning as African-Americans and Latinos are 
projected to have the largest increase in prevalence of 
diabetic eye disease.6 However, ethnic status has not been 
found to be independently associated with DFE rates 
in all studies.11 In this current investigation, there was 
only an association between ethnicity and longitudinal 
utilization in patients with mild DR, with Asians having 
the most DFEs per year. Adherence to follow-up recom-
mendations was consistently low across all ethnic/racial 
groups as shown in table 2.
non-statistically significant variables after adjustment
Insurance status is another variable that has been associ-
ated with DFE rates in population studies with sizeable 
proportions of patients without insurance status or access 
to free care.12 16–18 21 24 One study also found that among 
individuals with diabetes over 65 years of age, people 
who were dual eligible for Medicare and Medicaid 
were significantly less likely to receive DFEs compared 
with people eligible for Medicare alone (63% vs 75%; 
p<0.0001).20 We found insurance status to be associated 
with adherence rates and longitudinal utilization in the 
univariable analysis, with Medicaid patients having the 
lowest adherence rates and Medicare patients having the 
highest adherence rates. However, this association was 
not significant in multivariable analyses.
Several previous studies have found higher socio-
economic status (SES) to be associated with having 
DFEs.11 12 24 In a national representative sample of 
84 572 people, Brechner et al found that in people 
with insulin-dependent diabetes and annual incomes 
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over US$40 000, 72.9% had DFEs within the last year 
compared with 32.4% of people who had annual income 
less than US$10 000.11 We found SES was only associated 
with longitudinal utilization in patients with mild DR, 
not in initial DFE follow-up, and that patients of the two 
lower SES brackets had the most DFEs per year. Our find-
ings could be real or due to the fact that we imputed SES 
using each subject’s census tract location and dividing 
the census tracts for our patients into four quartiles based 
on relative SES. While this method for estimating SES 
has been previously validated, it is limited by relying on a 
patient’s address and it cannot differentiate SES of indi-
vidual people living in the same census tract.
Gender has been significantly associated with different 
DFE rates in a number of studies, with women consistently 
having higher rates of eye care compared with men.12 14 16 
This difference has been attributed to perceived need of 
care by each gender. According to the Behavioral Risk 
Factor Surveillance System, 42% of men with moder-
ate-to-severe vision loss reported no need to have an eye 
examination compared with 29% of women with similar 
vision loss.22 However, our study found no differences 
in initial follow-up or eye care utilization between men 
and women. Our results agree with a recent study from 
Paskin-Hall et al, who also found gender was not signifi-
cantly associated with annual DFE adherence.24
Distance from a healthcare facility or provider can be 
a barrier to care. Increased driving distance has been 
associated with poor glycemic control38 39 and lower use 
of insulin.40 One study found that people residing more 
than 10 miles from a diabetes management center were 
almost twice as likely to have HbA1C >7% compared with 
people living closer to the care center.39 In contrast, we 
only found an association between driving distance and 
longitudinal utilization in severe patients, with patients 
living 5–25 miles within our healthcare facility having the 
most DFEs per year. Patients living within 5 miles of our 
facility are more likely to be from medically underserved 
areas than patients living slightly further away. In addi-
tion, our population was in an urban area with a large 
public transportation system. Previous studies linking 
driving distance to decreased care utilization have been 
predominantly conducted in rural areas where public 
transportation is minimal or absent.
strengths and weaknesses
The strengths of our study include the large urban popu-
lation followed over 4 years, the ability to determine DFE 
adherence based on objective data rather than self-re-
port, and the ophthalmology clinical setting, which has 
not been previously characterized in terms of factors 
associated with adherence to follow-up eye care.
Weaknesses of our study included limited data 
concerning self-reported HbA1C levels and ethnicity, 
although we were able to impute ethnicity using a vali-
dated method.27 Another potential weakness is that we 
were only able to capture DFEs at our clinics. It is possible 
that some patients received follow-up eye care outside 
our clinics that was not captured in our data. Finally, 
although we attempted to gather extensive patient infor-
mation, as an observational study, there is a potential for 
unmeasured confounding of associations.
The results of this study have important clinical and 
public health implications. Primary care practitioners, 
diabetic specialists, and eye care providers in urban clin-
ical settings should identify people with diabetes at risk 
for poor follow-up in order to improve adherence rates, 
particularly:
 ► patients with normal vision;
 ► older patients with severe DR;
 ► patients with mild DR and no history of other eye 
diseases;
 ► patients with no ophthalmology documented 
HbA1C or blood glucose;
 ► smokers.
Population-based health programs can also target this 
cohort with specific educational interventions in order to 
increase eye care utilization among people with diabetes 
and attenuate the potential for severe visual disability 
from DR. While all patients with diabetes need to improve 
follow-up, targeting subgroups with low adherence rates 
could have a high impact and prevent progression to 
more severe DR.
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